Travere Therapeutics Provides Corporate Update and 2026 Outlook
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Business Wire
U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company positioned for successful commercial launch of FILSPARI in FSGS, if approvedPivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU to restart in 1Q 2026 SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be approximately $127 million. For the fiscal year 2025, the Company expects total U.S. net product sales to be approximately $410 million. The Company ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. The Company also provided an update on key corporate, clinical, and regulatory development initiatives, including anticipated 2026 milestones.“The fourth quarter closed out an exceptional year of commercial execution with FILSPARI, as o
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law FirmBusiness Wire
- Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential [Seeking Alpha]Seeking Alpha
- Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLCGlobeNewswire
- TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 1/13/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- TVTX's page on the SEC website